<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="utf8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Risteys – RHEUMA_SEROPOS_STRICT – detailed case counts by code</title>
		<style type="text/css">
body {
	font-family: sans-serif;
}
.bar-plot-full {
	width: 8rem;
	border-radius: 0.1rem;
	background-color: #f2f2f2;
}
.bar-plot-full div {
	background-color: #c7c7c7;
	height: 1rem;
	border-radius: 0.1rem;
}
		</style>
	</head>
	<body>

		<table>
			<tr>
				<th>Source</th>
				<th>Code</th>
				<th>Name</th>
				<th>Case count</th>
				<th>Share of cases (%)</th>
			</tr>

			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(202)_ICD10(M05)</td>
					<td>Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis</td>
					<td>1684</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 42.849872773536894%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(202)_ICD10(M058)</td>
					<td>Connective tissue diseases, rheumatoid arthritis and comparable disease, Other seropositive rheumatoid arthritis</td>
					<td>1671</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 42.51908396946565%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(M058)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Other seropositive rheumatoid arthritis</td>
					<td>978</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 24.885496183206108%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(M058)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Other seropositive rheumatoid arthritis</td>
					<td>885</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 22.519083969465647%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(M05)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis</td>
					<td>705</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 17.938931297709924%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(M05)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis</td>
					<td>575</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 14.631043256997456%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(202)_ICD10(M059)</td>
					<td>Connective tissue diseases, rheumatoid arthritis and comparable disease, Seropositive rheumatoid arthritis, unspecified</td>
					<td>176</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 4.478371501272265%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(291)_ICD10(M058)</td>
					<td>Tofacitinib, Other seropositive rheumatoid arthritis</td>
					<td>85</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 2.1628498727735366%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(3006)_ICD10(M058)</td>
					<td>Baricitinib, Other seropositive rheumatoid arthritis</td>
					<td>74</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.88295165394402%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(293)_ICD10(M058)</td>
					<td>Baricitinib, Other seropositive rheumatoid arthritis</td>
					<td>58</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 1.4758269720101782%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(291)_ICD10(M05)</td>
					<td>Tofacitinib, Seropositive rheumatoid arthritis</td>
					<td>37</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.94147582697201%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(M059)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Seropositive rheumatoid arthritis, unspecified</td>
					<td>37</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.94147582697201%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(3005)_ICD10(M058)</td>
					<td>Tofacitinib, Other seropositive rheumatoid arthritis</td>
					<td>34</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.8651399491094147%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(293)_ICD10(M05)</td>
					<td>Baricitinib, Seropositive rheumatoid arthritis</td>
					<td>30</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.7633587786259541%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(M059)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Seropositive rheumatoid arthritis, unspecified</td>
					<td>29</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.7379134860050891%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(3006)_ICD10(M05)</td>
					<td>Baricitinib, Seropositive rheumatoid arthritis</td>
					<td>25</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.6361323155216284%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(3005)_ICD10(M05)</td>
					<td>Tofacitinib, Seropositive rheumatoid arthritis</td>
					<td>19</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.48346055979643765%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(202)_ICD9(M05)</td>
					<td>Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found</td>
					<td>9</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.22900763358778628%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(313)_ICD10(M050)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Felty's syndrome</td>
					<td>6</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.15267175572519084%"></div>
						</div>
						
					</td>
				</tr>
			
				<tr>
					<td><abbr title="KELA drug reimbursment">REIMB</abbr></td>
					<td>REIMB_KELA(281)_ICD10(M050)</td>
					<td>Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Felty's syndrome</td>
					<td>5</td>
					<td>
						
						<div class="bar-plot-full">
							<div style="width: 0.1272264631043257%"></div>
						</div>
						
					</td>
				</tr>
			

		</table>

	</body>
</html>
